Double landmark for Cambridge Cancer Genomics
Cambridge Cancer Genomics (CCG.ai) has made a significant addition to its top team.
Senior translational oncology Fellow Dr Gianmarco Contino is a surgical oncologist and translational scientist who brings years of expertise in cancer genomic medicine and molecular biology. Dr Contino has extensive experience working at the interface of biology and the clinic, facilitating the development of new discoveries into benefits for patients.
CCG says he “is the perfect person to help develop CCG.ai’s technologies and partnerships, and get our clinical prediction tools into the hands of those who need it the most.”
Dr Contino said: “CCG is accelerating the advent of precision medicine for cancer patients bringing together high throughput sequencing data and machine learning – two major revolutions of our times. As a cancer doctor and scientist this is a fantastic opportunity to fast-track smarter treatment to our patients.”
Dr Contino has recently been appointed a clinical senior lecturer of Cancer Genomic Medicine and Upper GI Surgery consultant at the University of Birmingham and will work alongside these roles at CCG.ai.
Previously, he was a clinical lecturer at the University of Cambridge and Addenbrooke’s Hospital. He trained as a surgical oncologist and translational scientist in several institutions including the European Institute of Oncology (Milan), Harvard Medical School, Mass General Hospital (Boston), University of Illinois at Chicago and Imperial College (London).
Cambridge Cancer Genomics is a Y combinator backed startup building the software to enable data-driven precision oncology.
Its precision AI platform, OncOS, enables oncologists to provide more effective, personalised cancer treatment for everyone. CCG.ai’s technology analyses and interprets DNA from a cancer patient, providing genomic insights into individual tumours as they change and grow; gives actionable insights into therapeutic effectiveness; and delivers personalised treatment and trial recommendations.
The success keeps on coming for CCG.ai. Dr Hannah Thompson, chief product and people officer has been named on BioBeat’s annual 50 Movers and Shakers in BioBusiness report, highlighting the trailblazers and trendsetters shaping the future of the UK life sciences sector.
Nominated for her commitment to collaboration through her work and her focus on simplifying software for monitoring cancer patients, Hannah joins an illustrious list of leaders shaping the UK life sciences sector.
She has brought together cancer patients and oncologists for the development of an artificial intelligence platform for treatment monitoring; helping to secure the first industry access to data from Genomics England’s 100,000 Genomes Project.